Dana-Farber Cancer Institute | Strategic Alliance Partners

November 28, 2022

Dr Florez discusses why cancer care equity and survivorship should be a priority for all physicians, the steps the health care system needs to take to address disparities in these areas, and specific ways that Dana-Farber is working to close these gaps.

November 23, 2022

Mirvetuximab soravtansine has been granted accelerated approval by the U.S. Food and Drug Administration on November 14 for the treatment of recurrent platinum-resistant high-grade serous ovarian cancer that highly expresses folate receptor alpha.

November 15, 2022

Ursula A. Matulonis, MD, discusses the significance of the FDA approval of mirvetuximab soravtansine-gynx in patients with folate receptor α–positive, platinum-resistant ovarian cancer.

November 11, 2022

Because androgen deprivation therapy alone or with docetaxel is not recommended for most patients with metastatic castration-sensitive prostate cancer, a decision must be made between leveraging couplets vs triplets.

November 04, 2022

Bradley McGregor, MD, discusses the rationale behind combining belzutifan with lenvatinib in pretreated patients with advanced renal cell carcinoma with clear cell components.

November 04, 2022

Bradley McGregor, MD, discusses the factors that affect frontline treatment decisions for patients with advanced RCC, the importance of longer-term follow-up of phase 3 trials in kidney cancer, and the benefits of dual immunotherapy and immunotherapy/TKI treatment combinations.

November 01, 2022

Stephanie Berg, DO, discusses two key clinical trials that have advanced the standard of care in metastatic hormone-sensitive prostate cancer.

October 31, 2022

Guru P. Sonpavde, MD, discusses the investigation of enfortumab vedotin-ejfv with or without pembrolizumab in urothelial cancer.

October 20, 2022

Rana R. McKay, MD, discusses the evolution of frontline treatment options for metastatic RCC, and the key clinical trials that have shifted the treatment paradigms in metastatic castration-resistant prostate cancer, nonmetastatic castration-resistant prostate cancer, and advanced prostate cancer.

October 20, 2022

Richard M. Stone, MD, highlights how uproleselan disrupts E-selectin in the AML tumor microenvironment, the variety of AML regimens that uproleselan may amplify in efficacy, including chemotherapies and venetoclax combinations, and the need for further research to determine whether minimal residual disease negativity rates will improve patient prognoses.

October 17, 2022

Wenxin Xu, MD, discusses future considerations for the treatment of patients with kidney cancer. 

October 14, 2022

Christine Ryan, MD, discusses the significance of data for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

October 14, 2022

A computer platform developed at Dana-Farber Cancer Institute makes the matching process for clinical trials for patients with genomic alterations both easier and faster.

October 04, 2022

Dana-Farber Cancer Institute, one of the world’s leading cancer research and treatment centers, has partnered with the Parker Institute for Cancer Immunotherapy, the leading network of immuno-oncology expertise in the world, as a member of the PICI Network with a goal to better understand the tumor microenvironment across cancer types and translate these basic discoveries to the clinic as impactful cancer immunotherapies.

October 03, 2022

Study establishes rationale for combination approaches targeting multiple proteins — therapy produces responses in 70% of study participants, including those who who relapsed after prior CAR T therapy.

September 25, 2022

TAC01-HER2 demonstrated early signals of clinical activity with a tolerable safety profile in patients with HER2-overexpressed solid tumors.

September 12, 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

September 12, 2022

Belzutifan plus cabozantanib sustained antitumor activity in patients with advanced clear cell renal cell carcinoma who previously received immunotherapy.

September 12, 2022

The triplet regimen of cabozantinib plus standard-of-care nivolumab and ipilimumab reduced the risk of disease progression or death by 27% vs placebo in patients with advanced renal cell carcinoma.

September 11, 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.